Pharmaceutical Cannabis Derivatives Help Discover their Receptors and Functions for Autoimmune Illnesses
A recent study conducted by Michigan State University exposed the potential for cannabinoid receptor 2 (CB2) to target the treatment of inflammatory conditions. Elevated levels of plasmacytoid dendritic cells (pCD, a type of cell in the immune system) contribute to chronic inflammation in autoimmune diseases, such as Rheumatoid Arthritis. Researchers found that synthetic CB2 agonists reported comparable benefits to THC, but minimized the cerebral effects as the psychotropic activity is mediated by cannabinoid receptor 1 (CB1). This evidence demonstrates the potential benefits of CB2-targeted treatment for inflammatory conditions. Unfortunately, there are serious concerns about the misuse of some synthetic cannabinoids, so there is still a missing bridge, in products and public education, between these research products and potential therapeutic pharmaceuticals, down the road.
Overlaps in pharmacology for the treatment of chronic pain and mental health disorders
Select small trials have demonstrated cannabis to be more effective than other analgesics to treat chronic pain associated with certain conditions. However, the existing research lacks large-scale, controlled experiments relating medical cannabis use to pain management. Additionally, negative effects are documented with respect to cannabis use among adolescents and those suffering from compromised mental health. There is a need for further research on the topic.
Medical Cannabis and the Treatment of Obstructive Sleep Apnea: An American Academy of Sleep Medicine Position Statement
Obstructive sleep apnea is a sleep disorder causing episodic airway obstruction that results in the brief “apneic” (cessation of breathing) episodes for brief periods of time. A recent study investigating Dronabinol, a synthetic cannabis derivative, as a potential therapy for sleep apnea resulted in an improvement of 32% in the apnea-hypopnea index. However, the American Academy of Sleep Medicine does not endorse medical cannabis as a treatment for sleep apnea, due to what they point to as a lack of knowledge surrounding the long-term effects of its use. ” Based on these results, cannabis and its components should be further researched to determine its potential for sleep apnea treatment.
Because of the associated anti-inflammatory action, modulation of CB1R & CB2R is helpful to treat autoimmune diseases, including Multiple Sclerosis, Type-1 Diabetes Mellitus, and Rheumatoid Arthritis The full list is truly very much longer, as every illness necessarily involves the immune system and cellular communication.
The following review, written by Elaine D. Gonc ̧alves
In a study of 40 mice, scientists find that the CB2-selective agonist significantly reduced the severity of arthritis and markedly reduced bone erosion. These data clearly indicate that the CB2-selective agonist may be considered a novel treatment for rheumatoid arthritis.